

**You are invited to join the
PATHFINDER Study to help
improve early cancer detection.**



Your participation could help improve early cancer detection in the future.

What is the PATHFINDER Study?

Too often, cancer goes undetected until it is at an advanced stage. Thinking about the possibility of having cancer can feel overwhelming but taking steps to catch cancer early can make you feel more in control of your health. The earlier that cancer can be found, the higher the chance of survival.¹

The PATHFINDER Study will evaluate Galleri™, a test that has been designed to detect many types of cancer through one blood draw. As a participant of the study you will receive your Galleri test results. This test is meant to be used in addition to cancer screening tests your healthcare provider may recommend, such as colonoscopy or mammography.

¹ Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006-2015

About Galleri

Galleri is designed to **detect many types of cancer through one blood draw**. It looks for signals of cancer that may currently be present. If a signal that may be cancer is detected, Galleri is designed to identify the location in the body the signal may be coming from, for example, the lungs or the colon. This information helps healthcare providers determine the appropriate tests to confirm whether cancer is present. Galleri does not measure your genetic risk of developing cancer in the future.

Who can participate in the PATHFINDER Study?

The PATHFINDER Study is currently open to **men and women aged 50 years or older** who meet eligibility criteria and receive care at Compass Oncology or other participating health systems. Participants of previous or ongoing GRAIL sponsored studies are not eligible to participate in PATHFINDER.

What does participation involve?

Participants in PATHFINDER will be asked to: Read and sign an informed consent form that fully explains the study.

- Provide their medical history and complete an initial questionnaire
- Provide a blood sample (4 tubes) drawn by a trained practitioner
- Complete additional questionnaires during the follow-up period

If you are interested in enrolling or have additional questions, please contact your local Compass clinic stating that you are interested in learning more about the PATHFINDER Study;

Compass East – 503-239-7767

Compass West Cancer Center – 971-708-7600

Compass Vancouver Cancer Center – 360-944-9889

Compass Rose Quarter Cancer Center – 503-274-4885

CAUTION - Galleri is an investigational device. Limited by Federal law to investigational use.